Royalty Pharma plc Research and Development Expense
Royalty Pharma plc (RPRX) reported Research and Development Expense of $97.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Royalty Pharma plc research and development expense for the quarter ending 2026-06-30 was $97.85M, a 67.44% decline year-over-year.
- Royalty Pharma plc research and development expense for the quarter ending 2026-03-31 was $39.79M, a 21.21% decline year-over-year.
- Royalty Pharma plc research and development expense for the quarter ending 2025-12-31 was $50.50M, a 10000.00% increase year-over-year.
- Royalty Pharma plc research and development expense for the quarter ending 2025-09-30 was $50.50M, a 10000.00% increase year-over-year.
- Royalty Pharma plc research and development expense for fiscal 2025 was $452.00M, a 22500.00% increase from fiscal 2024.
- Royalty Pharma plc research and development expense for fiscal 2024 was $2.00M, a 96.15% decline from fiscal 2023.
- Royalty Pharma plc research and development expense for fiscal 2023 was $52.00M, a 70.64% decline from fiscal 2022.
- Royalty Pharma plc research and development expense for fiscal 2022 was $177.11M, a 11.48% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $97.85M 10-Q · filed 2026-08-05 | $137.64M 10-Q · filed 2026-08-05 | $188.14M derived: sum of 3 quarters · filed 2026-08-05 | $238.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $39.79M 10-Q · filed 2026-05-06 | $90.29M derived: sum of 2 quarters · filed 2026-05-06 | $140.79M derived: sum of 3 quarters · filed 2026-05-06 | $441.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $50.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $101.00M derived: sum of 2 quarters · filed 2026-02-11 | $401.50M derived: sum of 3 quarters · filed 2026-08-05 | $452.00M 10-K · filed 2026-02-11 |
| 2025-09-30 | $50.50M 10-Q · filed 2025-11-05 | $351.00M derived: sum of 2 quarters · filed 2026-08-05 | $401.50M 10-Q · filed 2025-11-05 | $402.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $300.50M 10-Q · filed 2026-08-05 | $351.00M 10-Q · filed 2026-08-05 | $351.50M derived: sum of 3 quarters · filed 2026-08-05 | $352.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $50.50M 10-Q · filed 2026-05-06 | $51.00M derived: sum of 2 quarters · filed 2026-05-06 | $51.50M derived: sum of 3 quarters · filed 2026-05-06 | $52.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.00M derived: sum of 2 quarters · filed 2026-02-11 | $1.50M derived: sum of 3 quarters · filed 2026-02-11 | $2.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | $500.00K 10-Q · filed 2025-11-05 | $1.00M derived: sum of 2 quarters · filed 2025-11-05 | $1.50M 10-Q · filed 2025-11-05 | $2.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $500.00K 10-Q · filed 2025-08-06 | $1.00M 10-Q · filed 2025-08-06 | $1.50M derived: sum of 3 quarters · filed 2026-02-11 | $52.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-08 | $1.00M derived: sum of 2 quarters · filed 2026-02-11 | $51.50M derived: sum of 3 quarters · filed 2026-02-11 | $52.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $51.00M derived: sum of 2 quarters · filed 2026-02-11 | $51.50M derived: sum of 3 quarters · filed 2026-02-11 | $52.00M 10-K · filed 2026-02-11 |
| 2023-09-30 | $50.50M 10-Q · filed 2024-11-06 | $51.00M derived: sum of 2 quarters · filed 2024-11-06 | $51.50M 10-Q · filed 2024-11-06 | $102.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $500.00K 10-Q · filed 2024-08-08 | $1.00M 10-Q · filed 2024-08-08 | $51.50M derived: sum of 3 quarters · filed 2025-02-12 | $77.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-09 | $51.00M derived: sum of 2 quarters · filed 2025-02-12 | $76.50M derived: sum of 3 quarters · filed 2025-02-12 | $77.11M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $50.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $76.00M derived: sum of 2 quarters · filed 2025-02-12 | $76.61M derived: sum of 3 quarters · filed 2025-02-12 | $177.11M 10-K · filed 2025-02-12 |
| 2022-09-30 | $25.50M 10-Q · filed 2023-11-08 | $26.11M derived: sum of 2 quarters · filed 2023-11-08 | $126.61M 10-Q · filed 2023-11-08 | $230.43M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $606.00K 10-Q · filed 2023-08-08 | $101.11M 10-Q · filed 2023-08-08 | $204.93M derived: sum of 3 quarters · filed 2024-02-15 | $295.43M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $100.50M 10-Q · filed 2023-05-09 | $204.32M derived: sum of 2 quarters · filed 2024-02-15 | $294.82M derived: sum of 3 quarters · filed 2024-02-15 | $297.94M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $103.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $194.32M derived: sum of 2 quarters · filed 2024-02-15 | $197.44M derived: sum of 3 quarters · filed 2024-02-15 | $200.08M 10-K · filed 2024-02-15 |
| 2021-09-30 | $90.50M 10-Q · filed 2022-11-08 | $93.62M derived: sum of 2 quarters · filed 2022-11-08 | $96.26M 10-Q · filed 2022-11-08 | $104.04M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $3.12M 10-Q · filed 2022-08-04 | $5.76M 10-Q · filed 2022-08-04 | $13.54M derived: sum of 3 quarters · filed 2023-02-15 | $18.64M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $2.64M 10-Q · filed 2022-05-05 | $10.42M derived: sum of 2 quarters · filed 2023-02-15 | $15.52M derived: sum of 3 quarters · filed 2023-02-15 | $21.29M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $7.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $12.88M derived: sum of 2 quarters · filed 2023-02-15 | $18.65M derived: sum of 3 quarters · filed 2023-02-15 | $26.29M 10-K · filed 2023-02-15 |
| 2020-09-30 | $5.10M 10-Q · filed 2021-11-10 | $10.87M derived: sum of 2 quarters · filed 2021-11-10 | $18.51M 10-Q · filed 2021-11-10 | $34.38M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $5.78M 10-Q · filed 2021-08-11 | $13.41M 10-Q · filed 2021-08-11 | $29.29M derived: sum of 3 quarters · filed 2022-02-15 | $52.00M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $7.64M 10-Q · filed 2021-05-11 | $23.51M derived: sum of 2 quarters · filed 2022-02-15 | $46.23M derived: sum of 3 quarters · filed 2022-02-15 | $67.68M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $15.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $38.59M derived: sum of 2 quarters · filed 2022-02-15 | $60.05M derived: sum of 3 quarters · filed 2022-02-15 | $83.04M 10-K · filed 2022-02-15 |
| 2019-09-30 | $22.72M 10-Q · filed 2020-11-12 | $44.17M derived: sum of 2 quarters · filed 2020-11-12 | $67.17M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $21.46M 10-Q · filed 2020-08-12 | $44.45M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $392.61M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |